z-logo
Premium
An Insulin‐like Growth Factor 2‐Derived Self‐Antigen Inducing a Regulatory Cytokine Profile after Presentation to Peripheral Blood Mononuclear Cells from DQ8 + Type 1 Diabetic Adolescents: Preliminary Design of a Thymus‐Based Tolerogenic Self‐Vaccination
Author(s) -
GEENEN V,
LOUIS C,
MARTENS H
Publication year - 2004
Publication title -
annals of the new york academy of sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.712
H-Index - 248
eISSN - 1749-6632
pISSN - 0077-8923
DOI - 10.1196/annals.1337.008
Subject(s) - peripheral blood mononuclear cell , cytokine , immunology , insulin , peripheral , peripheral blood , medicine , growth factor , antigen presentation , antigen , immune system , endocrinology , chemistry , t cell , biochemistry , in vitro , receptor
A bstract : This work aims to evaluate the potential use of insulin‐like growth factor 2 (IGF‐2) as the dominant thymic self‐antigen precursor of the insulin family in designing a tolerogenic approach to type 1 diabetes (T1D) prevention. This evaluation was primarily based on cytokine profile driven by MHC presentation of insulin and IGF‐2‐derived antigens to PBMC cultures derived from 16 T1D DQ8 + adolescents. Insulin B9‐23, one dominant β‐cell autoantigen, and the homologous sequence B11‐25 of IGF‐2 display the same affinity and fully compete for binding to DQ8, a MHC‐II allele conferring major genetic susceptibility to type 1 diabetes (T1D). However, compared to insulin B9‐23, presentation of IGF‐2 B11‐25 elicits a suppressive/regulatory cytokine profile with a higher number of IL‐10‐secreting cells ( P < 0.05 ), a much higher ratio of IL‐10/IFN‐γ ( P < 0.01 ), as well as a lower number of IL‐4‐secreting cells ( P < 0.05 ). Thus, with regard to T1D prevention, administration of IGF‐2‐derived self‐antigen(s) seems to be an efficient approach that combines both antagonism for binding to a major susceptibility MHC‐II allele, as well as downstream promotion of an antigen‐driven tolerogenic response.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here